Analytical Data
-
基因名
Claudin-6/CLDN6 Protein-VLP
- Application
-
别名
Claudin-6; Skullin; CLDN6; Claudin6; Skullin 2
-
种属
Human
-
表达系统
HEK293
-
标签
Tag Free
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P56747
-
表达区间
M1-V220
-
蛋白长度
Full Length
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Claudin-6 (CLDN6) is a member of the claudin family of tight junction proteins that play a critical role in maintaining the integrity of cell barriers. Its expression is notably high in various types of epithelial tissues and is often upregulated in certain cancers, making it a potential target for therapeutic interventions and vaccine development. Research into CLDN6 has garnered attention due to its ability to modulate paracellular permeability and its involvement in cell signaling pathways. The development of CLDN6 protein-based virus-like particles (VLPs) represents an innovative approach to harnessing the immunogenic properties of this protein for applications in immunotherapy and vaccine strategies. These VLPs can effectively mimic the structure of viruses, providing a platform for displaying CLDN6, which may enhance the immune response against CLDN6-expressing tumors. This approach is particularly promising in the context of cancer vaccines, where targeting tumor-specific antigens can stimulate robust immune responses while minimizing off-target effects. The ongoing research into CLDN6/CLDN6 VLP recombinant proteins aims to elucidate their potential as powerful tools for both therapeutic development and basic scientific insights into cellular functions and interactions in pathological conditions.
